临床化学多仪器同分析物网络化质控管理模型
该研究回顾性评估了一种质控模型,用于在两家地理站点共八台分析仪组成的网络中,对五种常见临床化学分析物采用统一Levey-Jennings质控图进行管理。模型以仪器供应商质量保证项目提供的同行组均值和限值设定靶值,采用13s/22s/R4s规则并结合统计与临床显著性评估。2023年2月至7月六个月结果显示各仪器偏倚与同行组均值无统计学或临床差异,质控错误率符合统计预期,无外部质量评估失败,未检测到超过TEa的误差,减少了不必要的校准和结果修改。
要点
- 采用同行组均值和限值设定统一质控图,适用于多仪器同分析物网络管理。
- 结合统计与临床显著性评估质控失败,可减少不必要的校准和结果修改。
- 持续监测仪器偏倚和精密度,确保网络内所有仪器满足临床质量目标。
核心结论
- 该质控模型成功实现了多仪器同分析物网络的质控管理,能持续评估单仪器偏倚与精密度并确保满足临床质量目标。
研究设计与样本
- 回顾性评估,在两家地理站点共八台分析仪组成的网络中,对五种常见临床化学分析物设计单一Levey-Jennings质控图,使用仪器供应商质量保证项目提供的同行组数据设定靶均值和限值。
主要发现
- 2023年2月至7月六个月间,各仪器偏倚与同行组平均值相比无统计学或临床差异。
- 该期间质控模型确定的错误率符合13s/22s/R4s规则的统计预期。
- 无外部质量评估失败,未检测到超过TEa的误差。
关键数值与推荐
- 质控规则为13s/22s/R4s,靶均值为来自同仪器大样本的同行组均值,限值基于同行组CV设定。
- 同时采用统计与临床显著性评估判定质控失败。
临床怎么用
- 该模型可用于实验室或实验室网络中对多台同分析物仪器进行统一质控管理。
- 结合统计与临床评估可减少不必要的校准和结果修改。
- 持续监测仪器偏倚和精密度,确保网络内所有仪器结果可比并降低患者风险。
局限性
- 原文未明确报告样本量、具体分析物名称、TEa具体数值及P值等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Monitoring quality control for a laboratory or network with multiple instruments measuring the same analyte is challenging. We present a retrospective assessment of a method to detect medically significant out-of-control error conditions across a group of instruments measuring the same analyte. The purpose of the model was to ensure that results from any of several instruments measuring the same analytes in a laboratory or a network of laboratories provide comparable results and reduce patient risk. Limited literature has described how to manage QC in these very common situations. METHODS: Single Levey-Jennings control charts were designed using peer group target mean and control limits for five common clinical chemistry analytes in a network of eight analyzers in two different geographical sites. The QC rules used were 13s/22s/R4s, with the mean being a peer group mean derived from a large population of the same instrument and the same QC batch mean and a group CV. The peer group data used to set the target means and limits were from a quality assurance program supplied by the instrument supplier. Both statistical and clinical assessments of significance were used to evaluate QC failure. Instrument bias was continually monitored. RESULTS: It was demonstrated that the biases of each instrument were not statistically or clinically different compared to the peer group's average over six months from February 2023 until July 2023. Over this period, the error rate determined by the QC model was consistent with statistical expectations for the 13s/22s/R4s rule. There were no external quality assurance failures, and no detected error exceeded the TEa (medical impact). Thus, the combined statistical/clinical assessment reduced unnecessary recalibrations and the need to amend results. CONCLUSIONS: This paper describes the successful implementation of a quality control model for monitoring a network of instruments, measuring the same analytes and using externally provided quality control targets. The model continually assesses individual instrument bias and imprecision while ensuring all instruments in the network meet clinical goals for quality. The focus of this approach is on detecting medically significant out-of-control error conditions.
引用
- Giannoli JM, Bernard M, L'Hirondel J, et al. A model for managing quality control for a network of clinical chemistry instruments measuring the same analyte. Clin Chem Lab Med. 2023. PMID: 37999926. doi:10.1515/cclm-2023-0965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。